Olapar 100 mg (Tablet)

Unit Price: ৳ 1,150.00 (1 x 24: ৳ 27,600.00)

Strip Price: ৳ 27,600.00

Medicine Details

Treatment of deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer
Maintenance treatment of platinum sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer

Inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes including PARP1, PARP2, and PARP3
Inhibition of tumor growth in select cell lines and mouse models
Increased cytotoxicity and anti-tumor activity in cell lines and mouse tumor models with deficiencies in BRCA
Rapid absorption with peak plasma concentrations typically achieved between 1 to 3 hours
Mean apparent volume of distribution at steady state of 167 ± 196 L
In vitro metabolism primarily by CYP3A4/5
Mean terminal plasma half-life of 11.9 ± 4.8 hours
Excretion of 86% of the dosed radioactivity within a 7-day collection period

Recommended dose of 400 mg (eight 50 mg capsules) taken orally twice daily with or without food
Dosage modifications for adverse reactions and use with CYP3A inhibitors
No established safety and efficacy in pediatric patients

Potentiation and prolongation of myelosuppressive toxicity when used in combination with other myelosuppressive anticancer agents
Alteration of plasma concentrations when co-administered with strong and moderate CYP3A inhibitors or inducers

Common serious adverse reactions include anemia, dermatitis allergic, neutrophil count decreased, and platelet count decreased
Proportion of patients who permanently discontinued due to adverse events was 4.9% in the Olaparib arm